The genetics and physiology of polycystic kidney disease

Seminars in Nephrology

Volumn 21, Issue 2, 2001, Pages 107-123

  Calvet, James P ^a   Grantham, Jared J ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALCIUM ION; CHLORIDE ION; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; POLYCYSTIN; POLYCYSTIN 1; POLYCYSTIN 2; PROTEIN KINASE C; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; CELL PROLIFERATION; CHLORIDE TRANSPORT; CLINICAL FEATURE; EXTRACELLULAR MATRIX; FLUID BALANCE; GENE INACTIVATION; GENE MUTATION; HUMAN; KIDNEY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 0035083551     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.20929     Document Type: Review

References (237)

1. Mechanisms of progression in autosomal dominant polycystic kidney disease
2. Autosomal dominant polycystic kidney disease
3. Natural history of autosomal dominant polycystic kidney disease
4. Extrarenal manifestations of autosomal dominant polycystic kidney disease
5. Bilateral polycystic disease of the kidneys
6. Composition of fluid in twelve cysts of a polycystic kidney
7. Ultrastructure and function of cysts from human adult polycystic kidneys
8. Cyst formation and growth in autosomal dominant polycystic kidney disease
9. A hereditary model of slowly progressive polycystic kidney disease in the mouse
10. Understanding human cystic disease through experimental models
11. Autosomal-dominant polycystic kidney disease in the rat
12. Animal models of polycystic kidney disease
13. Murine models of polycystic kidney disease
14. Autosomal dominant polycystic kidney disease: Clues to pathogenesis
15. Molecular basis of autosomal dominant polycystic kidney disease
16. Molecular genetics and mechanism of autosomal dominant polycystic kidney disease
17. Autosomal recessive polycystic kidney disease
18. Acquired cystic kidney disease
19. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium
20. Analysis of the genomic sequence for the autosomal dominant polycystic kidney disease (PKD1) gene predicts the presence of a leucine-rich repeat. The American PKD1 Consortium (APKD1 Consortium)
21. Polycystic kidney disease: The complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium
22. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains
23. Polycystic kidney disease. 1: Identification and analysis of the primary defect
24. Autosomal dominant polycystic kidney disease: Localization of the second gene to chromosome 4q13-q23
25. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease
26. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein
27. A gene similar to PKD1 maps to chromosome 4q22: A candidate gene for PKD2
28. Evidence for a third genetic locus for autosomal dominant polycystic kidney disease
29. Autosomal dominant polycystic kidney disease: Evidence for the existence of a third locus in a Portuguese family
30. Genetic heterogeneity of polycystic kidney disease in Bulgaria
31. An Italian family with autosomal dominant polycystic kidney disease unlinked to either the PKD1 or PKD2 gene
32. A family with a milder form of adult dominant polycystic kidney disease not linked to the PKD1 (16p) or PKD2 (4q) genes
33. Is there a third gene for autosomal dominant polycystic kidney disease?
34. Identification of mutations in the duplicated region of the polycystic kidney disease 1 gene (PKD1) by a novel approach
35. Mutation detection in the repeated part of the PKD1 gene
36. Identification of mutations in the repeated part of the autosomal dominant polycystic kidney disease type 1 gene, PKD1, by longrange PCR
37. Mutation detection of PKD1 identifies a novel mutation common to three families with aneurysms and/or very-early-onset disease
38. Screening of the PKD1 duplicated region reveals multiple single nucleotide polymorphisms and a de novo mutation in hellenic polycystic kidney disease families
39. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease - A contiguous gene syndrome
40. The mouse homologue of the polycystic kidney disease gene (Pkd1) is a single-copy gene
41. Chromosomal assignment of canine TSC2, PKD1 and CLN3 genes by radiation hybrid- and linkage analyses
42. The tuberin (TSC2), autosomal dominant polycystic kidney disease (PKD1), and somatostatin type V receptor (SSTR5) genes form a synteny group in the Fugu genome
43. Renal cystic disease in tuberous sclerosis: Role of the polycystic kidney disease 1 gene
44. A novel nonsense mutation in the PKD1 gene (C3817T) is associated with autosomal dominant polycystic kidney disease (ADPKD) in a large three-generation Italian family
45. Splicing mutations of the polycystic kidney disease 1 (PKD1) gene induced by intronic deletion
46. Autosomal dominant polycystic kidney disease (ADPKD) in an Italian family carrying a novel nonsense mutation and two missense changes in exons 44 and 45 of the PKD1 gene
47. Detection of a novel nonsense mutation and an intragenic polymorphism in the PKD1 gene of a Cypriot family with autosomal dominant polycystic kidney disease
48. Detection of two different nonsense mutations in exon 44 of the PKD1 gene in two unrelated Italian families with severe autosomal dominant polycystic kidney disease
49. Detection of translation terminating mutations in the PKD1 gene
50. Screening the 3′ region of the polycystic kidney disease 1 (PKD1) gene reveals six novel mutations
51. Mutations and intragenic polymorphisms in the diagnosis of autosomal dominant polycystic kidney disease type 1
52. A spectrum of mutations in the second gene for autosomal dominant polycystic kidney disease (PKD2)
53. Novel stop and frameshifting mutations in the autosomal dominant polycystic kidney disease 2 (PKD2) gene
54. Novel and recurrent mutations in the PKD1 (polycystic kidney disease) gene
55. A novel frameshift mutation induced by an adenosine insertion in the polycystic kidney disease 2 (PKD2) gene
56. A spectrum of mutations in the polycystic kidney disease-2 (PKD2) gene from eight Canadian kindreds
57. Recurrence of the PKD1 nonsense mutation Q4041X in Spanish, Italian, and British families
58. Mutational analysis within the 3′ region of the PKD1 gene
59. Novel mutations in the 3 region of the polycystic kidney disease 1 (PKD1) gene
60. Aberrant splicing in the PKD2 gene as a cause of polycystic kidney disease
61. Novel mutations in the duplicated region of PKD1 gene
62. Location of mutations within the PKD2 gene influences clinical outcome
63. Genetic evidence for a trans-heterozygous model for cystogenesis in autosomal dominant polycystic kidney disease
64. Segregation analysis of autosomal dominant polycystic kidney disease
65. Intracranial aneurysms in autosomal dominant polycystic kidney disease
66. Characteristics of very early onset autosomal dominant polycystic kidney disease
67. Spontaneous vertebral artery dissection as a complication of autosomal dominant polycystic kidney disease
68. Familial phenotype differences in PKD1
69. The polycystic kidney disease-1 protein, polycystin-1, binds and activates heterotrimeric G-proteins in vitro
70. Perinatal lethality with kidney and pancreas defects in mice with a targeted Pkd1 mutation
71. Late onset of renal and hepatic cysts in Pkd1-targeted heterozygotes
72. Polycystin 1 is required for the structural integrity of blood vessels
73. Cardiac defects and renal failure in mice with targeted mutations in Pkd2
74. Somatic inactivation of Pkd2 results in polycystic kidney disease
75. A human PKD1 transgene generates functional polycystin-1 in mice and is associated with a cystic phenotype
76. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I
77. Loss of the polycystic kidney disease (PKD1) region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for cyst pathogenesis
78. Loss of heterozygosity in polycystic kidney disease with a missense mutation in the repeated region of PKD1
79. Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease
80. Gene conversion is a likely cause of mutation in PKD1
81. A loss-of-function model for cystogenesis in human autosomal dominant polycystic kidney disease type 2
82. Somatic PKD2 mutations in individual kidney and liver cysts support a "two-hit" model of cystogenesis in type 2 autosomal dominant polycystic kidney disease
83. Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations
84. Identification and localization of polycystin, the PKD1 gene product
85. Polycystin, the polycystic kidney disease 1 protein, is expressed by epithelial cells in fetal, adult, and polycystic kidney
86. Polycystin: In vitro synthesis, in vivo tissue expression, and subcellular localization identifies a large membrane-associated protein
87. Molecular basis of renal cyst formation - One hit or two?
88. Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue
89. Loss of heterozygosity in renal and hepatic epithelial cystic cells from ADPKD1 patients
90. PKD1 interacts with PKD2 through a probable coiled-coil domain
91. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2
92. The pathogenesis of autosomal dominant polycystic kidney disease: An update
93. "Mistakes happen": Somatic mutation and disease
94. A 2.5 kb polypyrimidine tract in the PKD1 gene contains at least 23 H-DNA-forming sequences
95. Murine Pkd1 introns 21 and 22 lack the extreme polypyrimidine bias present in human PKD1
96. Phenotype and genotype heterogeneity in autosomal dominant polycystic kidney disease
97. Analysis of a large family with the second type of autosomal dominant polycystic kidney disease
98. Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients
99. Autosomal dominant polycystic kidney disease: Neoplasia in disguise?
100. Polypoid and papillary epithelial hyperplasia: A potential cause of ductal obstruction in adult polycystic disease
101. Renal epithelial hyperplastic and neoplastic proliferation in autosomal dominant polycystic kidney disease
102. New insights into polycystic kidney disease and its treatment
103. Somatic mutations are frequent and increase with age in human kidney epithelial cells
104. The Cre/loxP system and gene targeting in the kidney
105. The sea urchin sperm receptor for egg jelly is a modular protein with extensive homology to the human polycystic kidney disease protein, PKD1
106. The PLAT domain: A new piece in the PKD1 puzzle
107. A latrophilin/CL-1-like GPS domain in polycystin-1
108. The structure of a PKD domain from polycystin-1: Implications for polycystic kidney disease
109. The leucine-rich repeat: A versatile binding motif
110. Proteins with leucine-rich repeats
111. Structures and functions of multiligand lipoprotein receptors: Macrophage scavenger receptors and LDL receptor-related protein (LRP)
112. Functional importance of platelet-derived growth factor (PDGF) receptor extracellular immunoglobulin-like domains. Identification of PDGF binding site and neutralizing monoclonal antibodies
113. Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic kidney disease gene, PKD1
114. Comparative analysis of the polycystic kidney disease 1 (PKD1) gene reveals an integral membrane glycoprotein with multiple evolutionary conserved domains
115. The mouse homolog of PKD1: Sequence analysis and alternative splicing
116. Molecular cloning, cDNA sequence analysis, and chromosomal localization of mouse Pkd2
117. Characterization of the murine polycystic kidney disease (Pkd2) gene
118. Identification and characterization of polycystin-2, the PKD2 gene product
119. Polycystin-L is a calcium-regulated cation channel permeable to calcium ions
120. Genes homologous to the autosomal dominant polycystic kidney disease genes (PKD1 and PKD2)
121. The human polycystic kidney disease 2-like (PKDL) gene: Exon/intron structure and evidence for a novel splicing mechanism
122. Identification and characterization of a novel polycystin family member, polycystin-L2, in mouse and human: Sequence, expression, alternative splicing, and chromosomal localization
123. Signal transduction. Mating, channels and kidney cysts
124. Specific association of the gene product of PKD2 with the TRPC1 channel
125. Identification of a human homologue of the sea urchin receptor for egg jelly: A polycystic kidney disease-like protein
126. Polycystic kidney disease: Primary extracellular matrix abnormality or defective cellular differentiation?
127. Renal cell proliferation and the two faces of cyclic adenosine monophosphate
128. The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1
129. Cellular activation triggered by the autosomal dominant polycystic kidney disease gene product PKD2
130. Interaction between RGS7 and polycystin
131. The polycystic kidney disease 1 gene product modulates Wnt signaling
132. Identification of phosphorylation sites in the PKD1-encoded protein C-terminal domain
133. Identification of the major site of in vitro PKA phosphorylation in the polycystin-1 C-terminal cytosolic domain
134. The PKD1 gene product, "polycystin-1," is a tyrosine-phosphorylated protein that colocalizes with alpha2beta1-integrin in focal clusters in adherent renal epithelia
135. Quantitative trait loci modulate renal cystic disease severity in the mouse bpk model
136. Polycystin-1 activation of c-Jun N-Terminal Kinase (JNK) and AP-1 is mediated by heterotrimeric G-proteins
137. Construction of human embryonic cDNA libraries: HD, PKD1 and BRCA1 are transcribed widely during embryogenesis
138. Immunolocalization of polycystin in human tissues and cultured cells
139. Adult, fetal, and polycystic kidney expression of polycystin, the polycystic kidney disease-1 gene product
140. Characterization and cell distribution of polycystin, the product of autosomal dominant polycystic kidney disease gene 1
141. Distribution and developmentally regulated expression of murine polycystin
142. Polycystin expression is temporally and spatially regulated during renal development
143. Vascular expression of polycystin
144. Cellular localization and tissue distribution of polycystin-1
145. Polycystin-1 expression in PKD1, early-onset PKD1, and TSC2/PKD1 cystic tissue
146. Polycystin-2 expression is developmentally regulated
147. The role of the polycystins in kidney development
148. Characterisation and expression of the PKD-1 protein, polycystin, in renal and extrarenal tissues
149. Murine Pkd1 is a developmentally regulated gene from morula to adulthood: Role in tissue condensation and patterning
150. Distinct and common developmental expression patterns of the murine pkd2 and pkd1 genes
151. Cellular and subcellular distribution of polycystin-2, the protein product of the PKD2 gene
152. Expression of polycystin in mouse metanephros and extra-metanephric tissues
153. Polycystin expression during embryonic development of human kidney in adult tissues and ADPKD tissue
154. The polycystic kidney disease protein PKD2 interacts with Hax-1, a protein associated with the actin cytoskeleton
155. In vivo interaction of the adapter protein CD2AP with the type 2 polycystic kidney disease protein, polycystin-2
156. Focal overexpression of collagen IV characterizes the initiation of epithelial changes in polycystic kidney disease
157. Characterization of the Han: SPRD rat model for hereditary polycystic kidney disease
158. Viscoelastic properties of tubule basement membranes in experimental renal cystic disease
159. Tubular basement membrane change occurs pari passu with the development of cyst formation
160. Sequential tubular cell and basement membrane changes in polycystic kidney disease
161. Histogenesis of the renal cysts in adult (autosomal dominant) polycystic kidney disease: A histochemical study
162. Apoptosis and loss in renal tissue in polycystic kidney disease
163. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD)
164. Pathogenesis of autosomal dominant polycystic kidney disease: Role of apoptosis
165. Apoptosis in cystogenesis: Hands on or hands off?
166. Apoptosis in polycystic kidney disease: Involvement of caspases
167. Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease
168. Defective epidermal growth factor gene expression in mice with polycystic kidney disease
169. Elevated proto-oncogene expression in polycystic kidneys of the C57BL/6J (cpk) mouse
170. The SGP-2 gene is developmentally regulated in the mouse kidney and abnormally expressed in collecting duct cysts in polycystic kidney disease
171. C-fos expression is hypersensitive to serum-stimulation in cultured cystic kidney cells from the C57BL/6J-cpk mouse
172. Localization of overexpressed c-myc mRNA in polycystic kidneys of the cpk mouse
173. Growth factor gene expression in kidney of murine polycystic kidney disease
174. C-myc as an inducer of polycystic kidney disease in transgenic mice
175. Disappearance of polycystic kidney disease in revertant c-myc transgenic mice
176. Glomerulosclerosis and renal cysts in mice transgenic for the early region of SV40
177. Renal cyst formation and multifocal neoplasia in transgenic mice carrying the simian virus 40 early region
178. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD
179. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway
180. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells
181. Expression of a stably transfected C-terminal polycystin-1 construct transforms the cAMP growth-responsive phenotype of M-1 cells
182. The etiology, pathogenesis, and treatment of autosomal dominant polycystic kidney disease: Recent advances
183. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway
184. Differential effects of cAMP in neurons and astrocytes. Role of B-raf
185. Insertional mutagenesis and molecular analysis of a new gene associated with polycystic kidney disease
186. Functional correction of renal defects in a mouse model for ARPKD through expression of the cloned wild-type Tg737 cDNA
187. Cellular pathophysiology of cystic kidney disease: Insight into future therapies
188. In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor
189. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor
190. Time to treat polycystic kidney diseases like the neoplastic disorders that they are
191. Renal epithelial fluid secretion and cyst growth: The role of cyclic AMP
192. Renal epithelial cyst formation and enlargement in vitro: Dependence on cAMP
193. Anion secretion drives fluid secretion by monolayers of cultured human polycystic cells
194. Chloride and fluid secretion by cultured human polycystic kidney cells
195. Mechanisms of fluid secretion by polycystic epithelia
196. Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells
197. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro
198. Chloride and fluid secretion in polycystic kidney disease
199. Epithelial transport in polycystic kidney disease
200. BSC2 is the basolateral Na-K-2C1 cotransporter in a subset of cysts in autosomal dominant polycystic kidney disease
201. In vitro fluid secretion by epithelium from polycystic kidneys
202. ATP release mechanisms in primary cultures of epithelia derived from the cysts of polycystic kidneys
203. Nucleotides regulate NaCl transport in mIMCD-K2 cells via P2X and P2Y purinergic receptors
204. Water channel expression in human ADPKD kidneys
205. Expression of aquaporins-1 and -2 during nephrogenesis and in autosomal dominant polycystic kidney disease
206. Expression and localization of the water channels in human autosomal dominant polycystic kidney disease
207. Differentiation and cell polarity during renal cyst formation in the Han: SPRD (cy/+) rat, a model for ADPKD
208. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease
209. Reversed polarity of Na(+)-K(+)-ATPase: Mislocation to apical plasma membranes in polycystic kidney disease epithelia
210. Apical plasma membrane mispolarization of NaK-ATPase in polycystic kidney disease epithelia is associated with aberrant expression of the beta2 isoform
211. Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease
212. Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease
213. Evidence for inflammatory and secretagogue lipids in cyst fluids from patients with autosomal dominant polycystic kidney disease
214. Anion secretion by the inner medullary collecting duct. Evidence for involvement of the cystic fibrosis transmembrane conductance regulator
215. Ontogeny of apical membrane ion conductances and channel expression in cortical collecting duct cells
216. Cystic fibrosis transmembrane conductance regulator (CFTR) and renal function
217. CFTR mRNA and its truncated splice variant (TRN-CFTR) are differentially expressed during collecting duct ontogeny
218. Embryonic renal epithelia: Induction, nephrogenesis, and cell differentiation
219. Ca2+ and cAMP-activated Cl- conductances mediate Cl- secretion in a mouse renal inner medullary collecting duct cell line
220. Expression of the epithelial sodium channel (ENaC) during ontogenic differentiation of the renal cortical collecting duct epithelium
221. Epithelial ion transport in the fetal and perinatal lung
222. Expression of the epithelial Na+ channel in the developing rat lung
223. Ontogeny of alpha 1- and beta 1-isoforms of Na(+)-K(+)-ATPase in fetal distal rat lung epithelium
224. The role of active Na+ transport by lung epithelium in the clearance of airspace fluid
225. Decreased de novo synthesis of proteoglycans in drug-induced renal cystic disease
226. Comparison of proteoglycans synthesized by porcine normal and polycystic renal tubular epithelial cells in vitro
227. Altered synthesis and intracellular transport of proteoglycans by cyst-derived cells from human polycystic kidneys
228. Decreased synthesis and delayed processing of sulfated glycoproteins by cells from human polycystic kidneys
229. Altered extracellular matrix component gene expression in murine polycystic kidney
230. Morphology of basement membrane and associated matrix proteins in normal and pathological tissues
231. Basement membrane antigens in renal polycystic disease
232. Distribution of alpha-integrin subunits in fetal polycystic kidney diseases
233. Matrix metalloproteinases and TIMPS in cultured C57BL/6J-cpk kidney tubules
234. Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han: SPRD rat
235. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease
236. Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins
237. Compromised cytoarchitecture and polarized trafficking in autosomal dominant polycystic kidney disease cells